for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Clovis Oncology Announces Completion Of Target Enrollment In The Athena Trial, A Phase 3 Maintenance Treatment Study In Front-Line, Newly-Diagnosed Advanced Ovarian Cancer

June 10 (Reuters) - Clovis Oncology Inc:

* CLOVIS ONCOLOGY ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN THE ATHENA TRIAL, A PHASE 3 MAINTENANCE TREATMENT STUDY IN FRONT-LINE, NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER

* CLOVIS ONCOLOGY INC - TOPLINE DATA FOR RUBRACA MONOTHERAPY ARM VERSUS PLACEBO EXPECTED 2H 2021

* CLOVIS ONCOLOGY - TOPLINE DATA FROM RUBRACA & OPDIVO IN COMBINATION VERSUS RUBRACA MONOTHERAPY EXPECTED ONE YEAR OR MORE LATER Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up